The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing
owing to increased longevity of the general population and the availability of effective …

Multiple sclerosis (MS) is a disease of the central nervous system characterized by
inflammation, demyelination, and neuronal damage. Environmental and genetic factors are …

Overactivation of microglia is associated with most neurodegenerative diseases. In this
study we examined whether PET-measurable innate immune cell activation predicts multiple …

Despite that the availability of new therapeutic options has expanded the multiple sclerosis
(MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy …

Using combined endpoints to define no evident disease activity (NEDA) is becoming
increasingly common when setting targets for treatment outcomes in multiple sclerosis (MS) …

Pediatric-onset multiple sclerosis (POMS) is a rare neuroinflammatory and
neurodegenerative disease that has a significant impact on long-term physical and cognitive …

Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis
(MS) and monitoring its progression. However, the role of magnetic resonance imaging …

Background: A limited number of studies investigated associations between serum
neurofilament light chain (sNfL) and cognition in persons with multiple sclerosis (PwMS) …

Innovative pro-regenerative treatment strategies for progressive multiple sclerosis (PMS),
combining neuroprotection and immunomodulation, represent an unmet need. Neural …

Multiple sclerosis (MS), an inflammatory demyelinating and neurodegenerative disease of
the central nervous system, usually begins between the ages of 20 and 49 years, though in …